1997
DOI: 10.1016/s0049-0172(97)80034-0
|View full text |Cite
|
Sign up to set email alerts
|

Valvular dysfunction in antiphospholipid syndrome: Prevalence, clinical features, and treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

5
84
1
5

Year Published

1999
1999
2015
2015

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 147 publications
(95 citation statements)
references
References 34 publications
5
84
1
5
Order By: Relevance
“…4 Mitral regurgitation is the most common type of valvular abnormality, observed in 22% of patients with PAPS, followed by AR in 10%. 5 The pathogenesis of these valvular abnormalities in PAPS is not entirely clear. One possible initial event could be the binding of anticardiolipin antibodies to valvular endothelial cells.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…4 Mitral regurgitation is the most common type of valvular abnormality, observed in 22% of patients with PAPS, followed by AR in 10%. 5 The pathogenesis of these valvular abnormalities in PAPS is not entirely clear. One possible initial event could be the binding of anticardiolipin antibodies to valvular endothelial cells.…”
Section: Discussionmentioning
confidence: 99%
“…5 Nesher et al reported that the valve thickening in PAPS was generally diffuse, and when localized thickening was noted, it involved the leaflets' midportion or base. 5 In the present case, it was notable that the localized thickening and shrinkage were observed at the midportion and base of each cusp, with vegetation on the left ventricular side only, whereas the surface of the aortic valve on the side of the ascending aorta was smooth. Furthermore, none of the free edges of each valve were involved.…”
Section: Discussionmentioning
confidence: 99%
“…In the early 1990s, there were many reports of a link between antiphospholipid antibodies and valvular disease, but other studies failed to show a clear association (9). There were some case reports highlighting the efficacy of corticosteroids in remedying mitral valve dysfunction in patients who were antiphospholipid positive (11). Steroids were documented to not only remedy clinical symptoms attributable to heart failure from valvular dysfunction but also to rapidly decrease mitral valve leaflet thickness over time (11).…”
Section: Discussionmentioning
confidence: 99%
“…High-dose corticosteroids for 4 to 6 weeks are used to shrunken the vegetations, but this approach is controversial. ( Nesher et al, 1997) Some studies have suggested that corticosteroid treatment may contribute to ultimate valve thickening, but this is unproven. In the presence of significant regurgitation, even in the absence of nodules, there is a high risk of bacterial endocarditis particularly in the setting of jet lesions and warrant antibiotic prophylaxis.…”
Section: Treatmentmentioning
confidence: 99%